MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function

NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon^® TGFR for the assessment of kidney function in patients with normal or impaired renal function.

Read more at globenewswire.com